SLV213 Treatment in Ambulatory COVID-19 Patients

Selva Therapeutics

Status and phase

Not yet enrolling

Phase 2

Conditions

Covid19

Treatments

Drug: Placebo

Drug: SLV213

Study type

Interventional

Funder types

Industry

Other

Identifiers

NCT04843787

SLV213-02

Details and patient eligibility

About

This Phase 2a trial recruits adult ambulatory patients who have been determined to be COVID-19 positive. The study drug SLV213 will be administered to examine its safety, tolerability and provide assessment of its effect on clinical symptoms of COVID-19. Blood samples will be taken pre-dose and at several time points post-dose for pharmacokinetic (PK) analysis.

Full description

This double blind, placebo-controlled study will be conducted in two parts. Part A will determine the maximum tolerated dose (MTD) that will be used in Part B to confirm tolerance and provide assessment of the effect of SLV213 on clinical symptoms of COVID-19.

Part A will consist of three sequential cohorts of 12 subjects receiving treatment administered orally either twice a day or once a day for seven consecutive days. Subjects in each cohort will be randomized to one of two treatment arms, SLV213 (8 subjects) or placebo (4 subjects). After each cohort, a Selva Safety Review Committee (SRC) will evaluate the safety of the regimen before proceeding to dose the next cohort. If a cohort is deemed to have reached an intolerable dose level, the dose prior to that level will be the MTD. PK blood samples will be collected throughout the study.

In Part B of the study 45 subjects will be dosed at the MTD (30 SLV213 and 15 Placebo) to confirm tolerance, and to provide assessment of the effect of SLV213 on clinical symptoms of COVID-19. PK blood samples will be collected throughout the study.

Enrollment

81 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Agree to participate in the trial by signing the IRB approved Informed Consent
Age ≥ 18 years of age
Positive diagnosis for COVID-19 by SARS-CoV-2 PCR by nasopharyngeal swab within the past 3 days
Two or more COVID-19 symptoms (at least one of which must be Respiratory) rated Mild or Moderate on the COVID-19 adapted FLU-PRO Plus scale
SpO2 ≥ 94%
Ambulatory (not hospitalized) at the time of enrollment
Normal (or stable if abnormal per comorbidity) baseline ECG
Men of child-bearing potential must use birth control with heterosexual partner(s) (abstinence or condoms)
Women of child-bearing potential must meet all the following criteria:
- Use of birth control (abstinence, oral contraceptives, condoms, or intrauterine device)
- Test negative for β-subunit of HCG

Exclusion criteria

Pregnant or lactating
Treatment with COVID-19 antiviral such as remdesivir or SARS-CoV-2 antibodies
At increased risk of developing more severe COVID-19 disease (at least one of the following):
1. Age ≥60 years
2. Presence of pulmonary disease, specifically moderate or severe persistent asthma, chronic obstructive pulmonary disease, pulmonary hypertension, emphysema
3. Diabetes mellitus (type 1 or 2), requiring oral medication or insulin for treatment
4. Cardiovascular disease, including Hypertension, requiring at least 1 oral medication for treatment; congestive heart failure; coronary artery disease; cardiomyopathy; pulmonary hypertension
5. Body mass index ≥30
6. Chronic renal disease (but not on dialysis)
7. Sickle cell disease or trait
Severe or Critical COVID-19, as indicated by respiratory distress or shortness of breath at rest; Resp Rate ≥30/min; Heart rate ≥125/min; SpO2 ≤ 93% on room air or PaO2/FiO2 ≤ 300 if on supplemental O2
Positive HIV or positive Hepatitis Panel
Treatment with any medications known to be strongly metabolized by CYP3A4 or CYP2D6

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Sequential Assignment

Masking

Quadruple Blind

81 participants in 8 patient groups, including a placebo group

Experimental: Multiple Ascending Dose Cohort 1

Experimental group

Description:

Intervention: SLV213, 8 subjects will receive 200mg oral doses twice a day for seven consecutive days.

Treatment:

Drug: SLV213

Placebo Comparator: Multiple Ascending Dose Cohort 1

Placebo Comparator group

Description:

Intervention: Placebo, 4 subjects will receive an equivalent number of oral doses twice a day for seven consecutive days.

Treatment:

Drug: Placebo

Experimental: Multiple Ascending Dose Cohort 2

Experimental group

Description:

Intervention: SLV213, 8 subjects will receive 400mg oral doses twice a day for seven consecutive days.

Treatment:

Drug: SLV213

Placebo Comparator: Multiple Ascending Dose Cohort 2

Placebo Comparator group

Description:

Intervention: Placebo, 4 subjects will receive the equivalent number of oral doses twice a day for seven consecutive days.

Treatment:

Drug: Placebo

Experimental: Multiple Ascending Dose Cohort 3

Experimental group

Description:

Intervention: SLV213, 8 subjects will receive 800mg oral doses once a day for seven consecutive days.

Treatment:

Drug: SLV213

Placebo Comparator: Multiple Ascending Dose Cohort 3

Placebo Comparator group

Description:

Intervention: Placebo, 4 subjects will receive the equivalent number of oral doses once a day for seven consecutive days.

Treatment:

Drug: Placebo

Experimental: Multiple Ascending Dose Cohort 4

Experimental group

Description:

Intervention: SLV213, 30 subjects will receive the MTD (200mg twice a day, 400mg twice a day or 800 mg once a day) oral doses for seven consecutive days.

Treatment:

Drug: SLV213

Placebo Comparator: Multiple Ascending Dose Cohort 4

Placebo Comparator group

Description:

Intervention: Placebo, 15 subjects will receive the equivalent number of oral doses once a day or twice a day for seven consecutive days.

Treatment:

Drug: Placebo